Xofigo Ra-223 Radium Dichloride

The Department of Veterans Affairs, Veterans Health Administration, Network Contracting Office 17, has issued a Special Notice announcing its intent to award a sole source procurement contract to Cardinal Health. The contract involves the procurement of 2,500 units of XOFIGO (Radium-223 dichloride), a pharmaceutical product used in medical treatment. The VA intends to award this as a firm-fixed price contract based on a price agreement established by Bayer Healthcare. This notice serves as advance notification to the contracting community of the agency's procurement intentions. The anticipated contract will be awarded under the statutory authority of 41 U.S.C. 3304(a)(1), which permits procurement from a single responsible source when no other supplies or services can satisfy agency requirements.

The primary purpose of this Special Notice is to provide transparency regarding the VA's sole source procurement decision while allowing other potential contractors an opportunity to demonstrate their capabilities. Interested parties have seven days from the publication date of August 4, 2025, to submit capability statements, proposals, or quotations for the agency's consideration. The VA will evaluate any responses received to determine if comparable sources exist that would be more advantageous to the government. All responsible sources are eligible to participate by submitting their qualifications and proposals during this limited timeframe. If no affirmative written responses are received within the seven-day window, the VA will proceed to award the contract to Cardinal Health without further notice. The procurement is justified based on Bayer Healthcare's certification that Cardinal Health serves as the sole source for XOFIGO in the United States.